Showing results (291-300 of 454) with videos related to

Sort By:
Pageof 46
Gut|April 12, 2012
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisRoeland Zoutendijk, Jurrien G P Reijnders, Fabien Zoulim, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Assessing Liver Fibrosis Using the FIB4 Index in the Community SettingAlbert Blanco-Grau, Pablo Gabriel-Medina, Francisco Rodriguez-Algarra, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2024
Implementing a new HCV model of care for people who use drugsAndrea Herranz Mochales, Camila A Picchio, Aina Nicolàs, et al.
BMC Infectious Diseases|September 5, 2018
Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virusMaría Eugenia Soria, Josep Gregori, Qian Chen, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for previously treated chronic HCV genotype 1 infectionBruce R Bacon, Stuart C Gordon, Eric Lawitz, et al.
Alimentary Pharmacology & Therapeutics|August 28, 2024
Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective-prospective studyElena Vargas-Accarino, Ariadna Rando-Segura, Adriana Palom, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 12, 2006
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patientsFrederik Nevens, Jane N Zuckerman, Andrew K Burroughs, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infectionPatrick Marcellin, David K Wong, William Sievert, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Pageof 46